CHOP versus PMItCEBO with/without G-CSF in patients aged sixty years plus with non-hodgkin's lymphoma

A phase III trial comparing a cyclophosphamide, adriamycin, vincristine and prednisolone (CHOP) regimen to a mitoxantrone, cyclophosphamide, etoposide, bleomycin, vincristine and prednisolone (PMItCEBO) regimen with or without granulocyte colony-stimulating factor (G-CSF) in patients aged sixty years plus with non-hodgkin's lymphoma

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN98741793

Enrollment

880

Registered

2002-08-19

Start date

1996-12-01

Completion date

Unknown

Last updated

2018-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Hodgkin's lymphoma Cancer Non-Hodgkin's lymphoma

Interventions

1. CHOP/G-CSF Regimen: chemotherapy with cyclophosphamide, adriamycin, vincristine and prednisolone (CHOP), cycle repeated every 21 days for six to eight cycles plus G-CSF. 2. CHOP Regimen: chemothera

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged at least 60 years 2. Newly presenting aggressive non-Hodgkin's lymphoma 3. Bulky stage IA and stages IB - IV 4. Patients must be free from any other irreversible medical condition that would drastically limit their life span or prohibit the use of combination chemotherapy 5. Adequate renal, hepatic and cardiac function 6. No previous malignancy 7. No central nervous system (CNS) involvement with non-Hodgkin's lymphoma

Exclusion criteria

Exclusion criteria: Patients with lymphoblastic and Burkitt's lymphoma

Design outcomes

Primary

Measure	Time frame
Failure free survival	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026